论文部分内容阅读
目的 探讨标准型 Ｃ Ｄ４４（ Ｃ Ｄ４４ｓ） 在非小细胞肺癌（ Ｎ Ｓ Ｃ Ｌ Ｃ） 中的临床应用价值。方法 用免疫组织化学方法检测 Ｎ Ｓ Ｃ Ｌ Ｃ１８０ 例和淋巴结 Ｎ Ｓ Ｃ Ｌ Ｃ 转移癌５１ 例的石蜡标本 Ｃ Ｄ４４ｓ 表达强度，并对１８０ 例 Ｎ Ｓ Ｃ Ｌ Ｃ 的术中情况进行记录，对其中１４１ 例病人进行随访分析。结果 Ｃ Ｄ４４ｓ 强表达的 Ｎ Ｓ Ｃ Ｌ Ｃ 多为Ⅰ期，术中淋巴结转移率及４ 年转移率较低，病人生存期较长；淋巴结 Ｎ Ｓ Ｃ Ｌ Ｃ 转移癌的 Ｃ Ｄ４４ｓ 表达率较原发灶低。结论 Ｃ Ｄ４４ｓ 强表达的 Ｎ Ｓ Ｃ Ｌ Ｃ 病人多为早期，发生转移可能性较少，生存期较长，可能是 Ｎ Ｓ Ｃ Ｌ Ｃ 一个预后良好的指标。
Objective To investigate the clinical value of standard C D44 (C D44s) in non-small cell lung cancer (NSCLC). Methods Immunohistochemistry was used to detect the expression of C D44s in paraffin-embedded specimens from NSCLC 180 cases and NSCLC metastases in 51 cases. The intraoperative conditions of 180 NSCLC cases were recorded. Follow-up analysis was performed on 141 patients. Results The CSCs with strong C D44s expression were mostly stage I. The lymph node metastasis rate and 4-year metastasis rate were lower in patients with C D44s. The survival time of patients was longer; the C D44s expression rate of N S C L C metastases in lymph nodes was higher than that of the original. The stove is low. Conclusion The patients with strong CSCs expressed in C D44s are mostly early stage, with less possibility of metastasis and longer survival time, which may be a good indicator of NSCLC.